A shorter radiotherapy (RT) course proved its mettle in early-stage breast cancer in terms of lymphedema risk, without ...

Hello Health Rounds Readers! Today we highlight research findings reported at ESMO 2024, the annual meeting of the European ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Key oncology conferences like ASCO, ASH, and ESMO drive investment-informing clinical research, with recent ESMO 2024 data highlighting significant advancements in immunotherapy. Merck's ...

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market. It worked by rousing the body’s own immune cells to attack tumors. Within months, regulators had approved ...

But it’s an issue that scientists discussing the trials raised throughout ESMO. Merck partnered with Eisai back in 2018 to expand the latter company’s Lenvima into new cancer indications ...

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.

Jazz’s Global Head of R&D Robert Iannone, M.D., told Fierce Biotech ahead of ESMO that today’s updated results “reaffirm zanidatamab’s potential as a foundational treatment for patients ...

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

Press conference: 12:30-13:15 CEST - ESMO Press Conference room, CC3 and virtually Presidential Symposium III, Eyes to the future: 16:30-18:15 CEST - Barcelona Auditorium - Hall 2 Organ agnostic ...